Relmada Therapeutics (NASDAQ: RLMD) insider transactions
In the twelve months to 10 November 2026, executives and directors of Relmada Therapeutics reported 0 open-market sales and 6 open-market purchases of 439,165 shares ($1.8m), by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 10 September 2026 | Traversa Sergio | Chief Executive Officer | Open-market purchase | +100,000 | $4.10 | 1,500,000 | Form 4 |
| 10 September 2026 | Shenouda Maged | Chief Financial Officer | Open-market purchase | +79,800 | $4.25 | 1,000,000 | Form 4 |
| 9 September 2026 | Traversa Sergio | Chief Executive Officer | Open-market purchase | +100,000 | $4.18 | 1,400,000 | Form 4 |
| 9 September 2026 | Shenouda Maged | Chief Financial Officer | Open-market purchase | +120,200 | $4.20 | 920,200 | Form 4 |
| 15 December 2025 | Shenouda Maged | Chief Financial Officer | Open-market purchase | +11,665 | $4.12 | 800,000 | Form 4 |
| 15 December 2025 | Traversa Sergio | Chief Executive Officer | Open-market purchase | +27,500 | $4.12 | 1,300,000 | Form 4 |
| 5 November 2025 | Kelly Paul Edward | Chief Operating Officer | Open-market purchase | +90,000 | $2.20 | 502,295 | Form 4 |
| 5 November 2025 | Shenouda Maged | Chief Financial Officer | Open-market purchase | +500,000 | $2.20 | 788,335 | Form 4 |
| 5 November 2025 | Traversa Sergio | Chief Executive Officer | Open-market purchase | +272,500 | $2.20 | 1,272,500 | Form 4 |
| 5 November 2025 | Ence Chuck | CAO and COO | Open-market purchase | +136,000 | $2.20 | 403,931 | Form 4 |
| 28 August 2025 | Traversa Sergio | Chief Executive Officer | Open-market purchase | +55,976 | $0.74 | 1,000,000 | Form 4 |
| 27 August 2025 | Traversa Sergio | Chief Executive Officer | Open-market purchase | +129,455 | $0.67 | 944,024 | Form 4 |
| 26 August 2025 | Traversa Sergio | Chief Executive Officer | Open-market purchase | +80,545 | $0.62 | 814,569 | Form 4 |
| 20 May 2025 | Traversa Sergio | Chief Executive Officer | Open-market purchase | +147,686 | $0.56 | 734,024 | Form 4 |
| 20 May 2025 | Shenouda Maged | Chief Financial Officer | Open-market purchase | +60,000 | $0.52 | 288,335 | Form 4 |
| 19 May 2025 | Traversa Sergio | Chief Executive Officer | Open-market purchase | +30,000 | $0.50 | 586,338 | Form 4 |
| 19 May 2025 | Shenouda Maged | Chief Financial Officer | Open-market purchase | +90,000 | $0.49 | 228,335 | Form 4 |
| 16 May 2025 | Traversa Sergio | Chief Executive Officer | Open-market purchase | +172,314 | $0.45 | 556,338 | Form 4 |
| 16 May 2025 | Ence Chuck | CA and CO | Open-market purchase | +228,961 | $0.45 | 267,931 | Form 4 |
| 16 May 2025 | Shenouda Maged | Chief Financial Officer | Open-market purchase | +50,000 | $0.44 | 138,335 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Relmada Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.